IL-4 inhibits TLR-signaling, which would be reversed by ruxolitinib, but it also enhances BCR-signaling (Figure 4), suggesting CLL cells should become less activated in vivo if ruxolitinib was mainly blocking the effects of IL-4. Here, BCR is linked to B-cell chronic lymphocytic leukemia.